Comparison · NCT02135848-05feb9c3
GSK1278863 vs Placebo: Number of Participants With Clinical Hematology Abnormalities of Potential Clinical Importance
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GSK1278863 vs Placebo: Number of Participants With Clinical Hematology Abnormalities of Potential Clinical Importance. Trial comparisons, record NCT02135848-05feb9c3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02135848-05feb9c3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.129 | wilson | |
| Risk in group 2 | 0 | 0 | 0.161 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.161 | 0.129 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GSK1278863 | Eligible participants received an initial single high dose of 300 mg GSK1278863 tablets orally followed by a 14-day washout period. After completing the washout period, participants received repeated dose of 15 mg GSK1278863 tablets orally once daily for 14 days. | 0 | 26 | OG000 |
| Group 2 | Placebo | Eligible participants received placebo matched with 300 mg GSK1278863 tablets orally followed by a 14-day washout period. After completing the washout period, participants received placebo matched with 15 mg GSK1278863 tablets orally once daily for 14 days. | 0 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Clinical Hematology Abnormalities of Potential Clinical Importance
- Description
Hematology parameters included platelet count, red blood cell (RBC) count, white blood cell WBC count (absolute), hemoglobin, hematocrit, Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC), neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of participants with clinical hematology abnormalities of potential clinical importance are presented.
- Time frame
- Up to 67 days
- Population
- Safety Population.
Source ClinicalTrials.gov
Trial
- Title
- 3 Month PHI PAD PoM Study
- NCT number
- NCT02135848
- Phases
- PHASE2
- Conditions
- Vascular Disease, Peripheral
- Interventions
- GSK1278863, Placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2017-10-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02135848?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02135848-05feb9c3